Cidara (CDTX) Develops Next-Gen Immunotherapy Treatments

66
Cidara Therapeutics, Inc. (CDTX) is a biotechnology company focused on developing long-acting anti-infectives and immunotherapies. Its lead product, rezafungin, targets serious fungal infections, while its Cloudbreak® platform is designed to treat and prevent viral diseases. With growing global demand for innovative anti-infective solutions, CDTX is gaining attention for its targeted approach to unmet medical needs.

On the chart, CDTX recently formed a confirmation bar with rising volume and moved above the .236 Fibonacci level, entering the momentum zone. This signals increased interest from traders and potential for further upside. The .236 level can serve as a trailing stop reference using the Fibonacci snap tool to help manage risk while capturing additional gains.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.